Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Get the detailed quarterly/annual income statement for Recursion Pharmaceuticals, Inc. (RXRX). Find out the revenue, expenses and profit or loss over the last fiscal year.

An important aspect in software engineering is the ability to distinguish between premature, unnecessary, and necessary ...